MICROBIDE LIMITED

BEYOND CLEAN: The Next Generation in Bio-hazard Management

  • Stage Prototype Ready
  • Industry Chemicals and Chemical Products
  • Location Dublin, Ireland
  • Currency EUR
  • Founded February 2007
  • Employees 5
  • Incorporation Type Other
  • Website microbide.com

Company Summary

There is an urgent need for better disinfection and bio-hazard control options that can address a broad range of bio-safety challenges occurring around the globe. Microbide is developing a patent-protected disinfectant product line based on micelle-stabilized aldehydes.
Microbide’s products are:
1-safer and more efficacious than corresponding products,
2-have a much broader range of use,
3-have longer shelf-life, and
4-many are biodegradable.

Team

  • Mary Skelly
    Chief Executive Officer

    Mary is a seasoned executive with more than 30 years in the pharmaceuticals and consumer products industries. She has significant experience in Regulatory Affairs and Business Development. Her career in the US included positions at Pfizer, American Cyanamid and The Procter & Gamble Company. For the last 20 years she has worked with the lifescience academic and start-up communities in Ireland.

  • Dierdre McDonnell-Lee
    Director of Operations

    Dr McDonnell-Lee has a PhD in Polymer Chemistry. Deirdre has previously worked in the medical device industry in the US and has also worked for the Irish government while in NYC.

  • Dr Michael Kennedy
    Chief Chemist

    Dr Kennedy has significant experience in manufacturing process development, with a particular expertise in explosive organic reactions. He has been a consultant for many years to the pharmaceutical manufacturing industry in Ireland, as well as academic positions with the National University of Ireland in Maynooth and Galway.

  • Bryony Carroll
    Finance Director

  • James McCarthy
    President, North America

    Jim, a seasoned business development professional, has forty years of life sciences professional experiences including a 25 year career with Bristol-Myers Squibb and Eli Lilly & Company and over 15 years in international corporate business development and licensing roles. These included deals in over 30 countries with over 80 agreements valued at > $900 million.
    Jim holds an MBA from Indiana University, a B.S. in Physical Therapy from SUNY.

Advisors

Previous Investors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free